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The objective was to determine the mRNA expression and protein levels of uPA system components in tissue specimens and serum
samples, respectively, from prostate cancer (PCa) patients and to assess their association with clinicopathological parameters and
overall survival (OS). The mRNA expression levels of uPA, its receptor (uPAR), and its inhibitor type 1 (PAI-1) were analyzed in
corresponding malignant and adjacent nonmalignant tissue specimens from 132 PCa patients by quantitative PCR. Preoperative
serum samples from 81 PCa patients were analyzed for antigen levels of uPA systemmembers by ELISA. RNA levels of uPA system
components displayed significant correlationswith each other in the tumor tissues. A significantly decreased uPAmRNAexpression
in PCa compared to the corresponding nonmalignant tissue was detected. High uPAmRNA level was significantly associated with
a high Gleason score. Elevated concentration of soluble uPAR (suPAR) in serumwas significantly associated with a poor OS of PCa
patients (𝑃 = 0.022). PCa patients with high suPAR levels have a significantly higher risk of death (multivariate Cox’s regression
analysis; HR = 7.12, 𝑃 = 0.027). The association of high suPAR levels with poor survival of PCa patients suggests a prognostic
impact of suPAR levels in serum of cancer patients.
1. Introduction
Prostate cancer (PCa) is the second most frequently diag-
nosed malignancy and the sixth leading cause of cancer-
related death in men worldwide [1]. Several biomarkers for
PCa have been described either in tumor tissue or urine
[2, 3]. However, further research and validation of these
molecular markers for diagnostic and prognostic purposes in
PCa patients are still necessary.
The urokinase-type plasminogen activator (uPA) system
has been shown to play a key role in physiological and patho-
logical pathways including cancer [4–7]. It consists mainly of
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uPA, the uPA receptor (uPAR), and the plasminogen activator
inhibitor-1 (PAI-1). The uPA system is causally involved in
multiple steps of cancer progression [6, 8, 9]. In addition to
extracellular proteolysis, uPA in concert with uPAR and/or
PAI-1 induces cell signaling pathways that affect tumor-
associated processes such as angiogenesis, cell growth, cell
adhesion and migration, chemotaxis, and cell survival [7, 8].
High expression levels of the uPA systemmembers have been
found to be associated with clinicopathological parameters
and have an impact on disease prognosis in a variety of cancer
types including prostate cancer [10–12].
In PCa, high uPA, uPAR, and/or PAI-1 protein expres-
sion in tumor tissue detected by immunohistochemistry
(IHC) has been shown to be significantly associated with
clinical prognostic parameters. Significant associations were
observed between high immunoexpression of uPA and/or
uPAR and a high Gleason score (GS), high tumor stage (pT),
positive lymph node status, and incomplete tumor resection
(R1) [13, 14]. Additionally, strong PAI-1 immunostaining was
associated with high pT and R1 status [14]. Furthermore, bio-
chemical recurrence-free survival of PCa patients with strong
uPA, uPAR, and PAI-1 staining by IHC was significantly
shorter than that of patients with weak staining [14]. Other
research groups did not find significant associations between
high uPA or PAI-1 immunoexpression and clinicopathologi-
cal parameters [15]. However, the combined high uPA/PAI-
1 immunoexpression was related to adverse pathological
features, shorter overall survival (OS), and aggressive disease
recurrence [15].
Only one study has been performed so far analyzing
mRNA levels of the uPA system members in PCa tissues
with regard to potential associations with clinicopathological
data [16]. In that study, an increased mRNA expression of
uPA and PAI-1 in PCa tissue compared to benign prostatic
hyperplasia (BPH) tissues was detected. Furthermore, the
mRNA expression of uPAR and PAI-1 was found to be
associated with GS [16].
With regard to uPA, soluble uPAR (suPAR), and/or PAI-
1 antigen levels in blood samples of PCa patients only few
studies exist [17–20]. Elevated levels of either uPA or suPAR
or elevated levels of both proteins in serum samples of PCa
patients were found to be associated with shorter OS [17].
The pretreatment plasma levels of uPA and suPAR were
mainly associated with early biochemical progression after
radical prostatectomy [18]. In addition, by using specific
immunoassay formats to detect individual, cleaved forms
of suPAR in serum of PCa patients, the specificity of PCa
detection may be improved [21]. Furthermore, using these
assays to analyze suPAR (variant) levels in a cohort of 131
metastatic PCa patients it was demonstrated that high levels
of all measured suPAR forms (including full-length suPAR)
were significantly associated with a shorter OS [20].
In the present study of 132 PCa patients, the mRNA levels
of uPA, uPAR, and PAI-1 were determined by quantitative
PCR (qPCR) in tissue specimens. In addition, antigen con-
centrations of uPA system members were determined in
preoperative serum samples from 81 of the 132 PCa patients
and 36 patients with BPH by ELISA. Both the mRNA
levels in tissue and the serum antigen concentrations were
analyzed for correlations among these factors themselves as
well as for their potential association with clinicopathological
parameters and OS of the PCa patients.
2. Materials and Methods
2.1. Patients and Clinical Samples. The mRNA expression
levels of uPA, uPAR, and PAI-1 were analyzed in correspond-
ing malignant and adjacent nonmalignant prostate tissue
samples of 132 nonselected PCa patients from two different
urological centers. All of the patients in this study underwent
radical prostatectomy at either the Department of Urology
of the Technische Universita¨t Dresden, Germany, or the
Department of Urology of the University of Regensburg,
Germany. The study was performed in compliance with the
Helsinki Declaration. The use of prostatectomy tissues for
research was approved by the Internal Review Boards from
the Medical Faculties of the Universities of Dresden and
Regensburg. All patients gave written informed consent.
The median age of the patients at surgery was 65 years
(range 46–78 years). The median follow-up time after pri-
mary tumor resection was 83 months (range 14–150 months).
During the follow-up period, 14 of the 132 patients (11%) died.
The tumors were staged according to the UICC system and
were graded according to the GS system.
From 81 out of the 132 PCa patients preoperatively col-
lected serum samples were additionally available for the
determination of antigen levels of uPA, suPAR, and PAI-1 in
serum by ELISA. The median age in this patient subgroup
was 65 years (range 48–77 years). The disease course of these
patients was followed for a median period of 88 months
(range 15–150 months) after surgery. During the follow-up
period, seven of the 81 patients (8.6%) died. In addition,
serum samples from 36 patients with BPH were available for
analysis.Themedian age of BPH patients was 68 years (range
40–84 years). The relevant clinicopathological parameters of
the PCa patient cohort are presented in Tables 1(a) and 1(b).
As there were only a few cases in our PCa cohort where
cancer-specific death was documented, the overall survival
defined as the time from radical prostatectomy to death or
last contact (of any cause) or last contact of the PCa patients
was used as follow-up end point.
2.2. Determination of mRNA Tissue Levels of uPA System
Members by Quantitative PCR. Only tumor tissue samples
with ≥70% cancer cells in the epithelial cell population and
adjacent nonmalignant prostate tissue samples with less than
5% cancer cells were included. Total RNAwas extracted from
paired samples of malignant and nonmalignant tissues from
each patient with the InviTrap Spin Tissue RNA Mini Kit
(STRATEC Molecular GmbH, Berlin, Germany) according
to the manufacturer’s protocols. The cDNA synthesis was
performed using Superscript II Reverse Transcriptase (Life
Science/Invitrogen, Karlsruhe, Germany) according to the
manufacturer’s instructions.
Gene-specific primers and hybridization probes were
used for the quantification of uPA, PAI-1, and uPAR
mRNA levels (LC FastStart DNA Master Hybridization
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Probes; Roche Diagnostics, Mannheim, Germany) using
Light Cycler technology (Roche) as previously described
[22, 23]. Primer sequences, concentrations of primers and
probes, and PCR conditions for amplification were as pre-
viously reported in detail ([24] and Supplemental Data
Table 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2014/972587). Six-log-range calibra-
tion curves were generated in each PCR run using PCR
vessels coated with defined numbers of linearized plasmid
molecules (101–106 molecules), carrying cDNA fragments of
either uPA, PAI-1, uPAR, or TATA box binding protein (TBP)
(AJ Roboscreen, Leipzig, Germany).Themeasurements were
performed in independent duplicates using aliquots of the
same cDNA dilutions to ensure comparable conditions.
The absolute quantification of gene expression was per-
formed by the LightCycler software (LightCycler 480 SW 1.5,
Roche). Relative mRNA expression levels of uPA, uPAR, and
PAI-1 normalized to TBPwere used for all statistical analyses.
2.3. Quantification of uPA System Member Protein Levels in
Serum by ELISA. Serum samples obtained from 81 of the
132 PCa patients prior to radical prostatectomy and from
36 BPH patients were stored at −80∘C until use. Antigen
concentrations (ng/mL) of uPA, suPAR, and PAI-1 in serum
samples were measured by specific ELISA formats (IMU-
BIND uPA ELISA #894, IMUBIND uPAR ELISA #893, and
IMUBIND PAI-1 ELISA #821; Sekisui/American Diagnostica
Inc., Stamford, CT, USA) according to the manufacturer’s
instructions.
2.4. Statistical Analysis. Correlations between continuous
variables of the biological markers were calculated by Spear-
man’s rank correlation test (𝑟
𝑠
).The relationships between the
biological marker expression levels and clinicopathological
parameters were assessed by Fisher’s exact test. For this, the
expression levels of uPA system members were separated
by the median into low and high expression groups. The
differences between mRNA expression levels of uPA sys-
tem components in malignant and nonmalignant prostate
tissues and between antigen concentrations in serum of
PCa patients and BPH patients were estimated by Mann-
Whitney 𝑈 test. For survival analyses, OS, defined as the
time from radical prostatectomy to death or last contact of
the PCa patients, was used as follow-up end point. Statistical
analyses of the association between the uPA systemmembers
and prognosis were performed using the Cox’s proportional
hazard regression model. The multivariate Cox’s regression
model was adjusted to relevant clinical prognostic factors:
age, lymph node status, pT, and GS. The survival curves
were estimated by Kaplan-Meier analysis (log-rank test). All
calculations were performed using the SPSS 21.0 statistical
package (SPSS-Science, Chicago, IL). The significance level
was set at 𝛼 = 0.05 and adjusted for multiple testing using
Bonferroni correction.
3. Results
3.1. Relationship between mRNA Expression Levels of uPA
SystemMembers inMalignant andNonmalignant Tissues from
PCa Patients. All relative mRNA levels of the uPA system
components displayed strong, significant, and positive corre-
lations with each other. The relative mRNA expression levels
of uPA correlated significantly with those of uPAR (𝑟
𝑠
=
0.550; 𝑃 < 0.001) and PAI-1 (𝑟
𝑠
= 0.552; 𝑃 < 0.001).
In addition, a significant positive correlation was observed
between the relative mRNA expression levels of uPAR and
PAI-1 (𝑟
𝑠
= 0.643; 𝑃 < 0.001).
The comparison of mRNA expression of uPA system
members in malignant tissue and adjacent nonmalignant
tissue revealed that uPA mRNA expression values were sig-
nificantly lower in the malignant tissue samples (𝑃 = 0.004).
No significant differences occurred between malignant and
adjacent nonmalignant PCa tissue for the expression of uPAR
and PAI-1 (Supplemental Data Table 2A).
3.2. Associations between mRNA Expression Levels of uPA
System Members in Tumor Tissue and Clinicopathological
Parameters and Overall Survival of PCa Patients. The nor-
malized relative mRNA expression values of uPA, uPAR, and
PAI-1 in tumor tissue ranged from 0.08 to 11.48 (median
0.38), from 0.04 to 8.61 (median 0.47), and from 0.09 to
121.7 (median 1.75), respectively (Supplemental Data Table
2A). For statistical analyses, uPA, uPAR, and PAI-1 mRNA
expression levels were stratified by the median values to
separate PCa patients into groups with low and high tissue
mRNA expression. The associations of mRNA expression
levels with clinicopathological parameters of the PCa patients
such as age, lymph node status, GS, and pT stage are summa-
rized in Table 1(a). High uPA mRNA expression levels were
significantly associated with high GS (𝑃 = 0.001; Table 1(a);
Figure 1(a)). However, there was no association between the
mRNA expression levels of the uPA systemmembers and age,
lymphnode status, or tumor stage (Table 1(a)).No association
betweenmRNA expression of uPA systemmembers in tumor
tissues and OS of the PCa patients was observed (data not
shown).
3.3. Relationship between Antigen Levels of uPA System Mem-
bers in Serum of PCa and BPH Patients. The concentrations
of uPA, suPAR, and PAI-1 antigen were determined in
preoperative serum samples of 81 PCa patients by ELISA.
The median antigen concentrations were 0.68 ng/mL (range:
0.43–1.88), 0.76 ng/mL (range: 0.20–26.2), and 1347.9 ng/mL
(range: 557.5–2714.0) for uPA, suPAR, and PAI-1, respectively
(Supplemental Data Table 2B). The serum concentration of
the uPA system members in PCa patients displayed only a
rather weak but significant positive correlation in case of
uPA versus suPAR (𝑟
𝑠
= 0.382; 𝑃 < 0.001). There were
no correlations found between uPA and PAI-1 and suPAR
and PAI-1 antigen levels in serum (𝑟
𝑠
= 0.035; 𝑃 = 0.756,
and 𝑟
𝑠
= 0.133; 𝑃 = 0.235, respectively). Likewise, in BPH
patients a weak correlation was observed only between uPA
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Table 1: (a) Relationship between clinicopathological parameters and mRNA expression levels of uPA system members in tumor tissues of
PCa patients (𝑛 = 132). (b) Relationship between clinicopathological parameters and antigen levels of uPA system members in the serum of
PCa patients (𝑛 = 81).
(a)
Clinicopathological parameters Number of cases uPA low/high uPAR low/high PAI-1 low/high
132
Age 𝑃 = 0.602 𝑃 = 1.000 𝑃 = 0.602
<65 yrs 66 35/31 33/33 35/31
≥65 yrs 66 31/35 33/33 31/35
Lymph node status∗ 𝑃 = 0.796 𝑃 = 0.795 𝑃 = 0.434
pN0 107 56/51 57/50 58/49
pN1 17 8/9 8/9 7/10
Tumor stage 𝑃 = 0.081 𝑃 = 0.296 𝑃 = 0.163
pT2 69 40/29 38/31 39/30
pT3 + 4 63 26/37 28/35 27/36
Gleason score P = 0.001 𝑃 = 0.199 𝑃 = 0.007
GS < 7 35 19/16 21/14 17/18
GS = 7 56 36/20 28/28 36/20
GS > 7 41 11/30 17/24 13/28
Statistical analysis was performed using Fisher’s exact test. Significant value is marked in bold. The Bonferroni-adjusted threshold for significance is at
𝛼 = 0.0042.
∗Number of patients 𝑛 = 124.
(b)
Clinicopathological parameters Number of cases uPA low/high uPAR low/high PAI-1 low/high
81
Age 𝑃 = 0.025 𝑃 = 0.377 𝑃 = 0.508
<65 yrs 40 25/14 23/17 22/18
≥65 yrs 41 15/26 19/22 19/22
Lymph node status∗ 𝑃 = 0.311 𝑃 = 0.5185 𝑃 = 0.311
pN0 69 36/33 36/33 33/36
pN1 10 3/7 4/6 7/3
Tumor stage 𝑃 = 0.263 𝑃 = 0.508 𝑃 = 0.825
pT2 43 24/19 24/19 21/22
pT3 + 4 38 16/22 18/20 19/19
Gleason score 𝑃 = 0.159 𝑃 = 0.838 𝑃 = 0.429
GS < 7 18 7/11 9/9 8/10
GS = 7 42 25/17 23/19 19/23
GS > 7 21 8/13 10/11 13/8
Statistical analysis was performed using Fisher’s exact test. The Bonferroni-adjusted threshold for significance is at 𝛼 = 0.0042.
∗Number of patients 𝑛 = 79.
and suPAR serum values (𝑟
𝑠
= 0.407; 𝑃 = 0.016, with Bon-
ferroni correction 𝛼 = 0.017).
In addition, there were no significant differences in serum
antigen levels of uPA system members between PCa and
BPHpatients (SupplementalData Table 2B). Furthermore, no
correlation was detected between antigen levels and mRNA
levels of uPA system components in serum and tissue of PCa
patients, respectively (data not shown).
3.4. Associations between Antigen Levels of uPA System Mem-
bers in Serum and Clinicopathological Parameters and Overall
Survival of PCa Patients. After stratifying uPA, suPAR, and
PAI-1 antigen values of PCa patients into low andhigh expres-
sion groups by the median values, potential associations
with clinicopathological parameters of the PCa patients were
assessed. The serum antigen levels showed no association
with clinicopathological features of PCa patients (Table 1(b);
Figure 1(b)).
For survival analyses we separated the PCa patients by
the 33% percentiles (tertiles) into three groups with low,
intermediate, or high serum levels of the uPA system com-
ponents according to Almasi et al. [20]. Next we subsumed
the patients with a low and intermediate serum level (0–
66% percentile) and compared them to the group with
high serum levels (>66–100% percentile) of the uPA system
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Table 2: Univariate and multivariate Cox’s regression analysis of the association of uPA, PAI-1, and uPAR serum levels in PCa patients with
OS (𝑛 = 81).
Parameters Number of cases Univariate analysis 𝑃 Multivariate analysis
1
𝑃
Multivariate analysis2
𝑃
HR (95% CI) HR (95% CI) HR (95% CI)
81
uPA serum∗
Low/intermediate 54 1 1 1.15 (0.12–6.42) 0.890
High 27 3.34 (0.73–15.20) 0.119 2.49 (0.51–12.25) 0.261 1
PAI-1 serum∗
Low/intermediate 54 1 1 1
High 27 2.53 (0.56–11.30) 0.226 4.94 (0.85–28.76) 0.076 3.06 (0.53–17.55) 0.209
uPAR serum∗
Low/intermediate 54 1 1 1
High 27 5.48 (1.06–28.29) 0.042 7.12 (1.25–40.69) 0.027 5.64 (0.79–40.35) 0.085
HR: hazard ratio (95% confidence interval) of the univariate and multivariate Cox’s regression hazard analysis.
Multivariate analysis was adjusted to relevant clinicopathological parameters: 1age, lymph node status, tumor stage, and Gleason score.
2Age, lymph node status, tumor stage, and Gleason score and with all three uPA components covariates added at once.
∗Serum antigen levels of uPA system components (ng/mL) were divided into low, intermediate, and high levels by the 33% percentiles (tertiles);
low/intermediate: 0–66% percentile; high: >66–100% percentile.
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Figure 1: Levels of uPA systemmembers in tumor tissues and serum in relation to Gleason score.The Gleason score was separated into three
groups: GS < 7, GS = 7, and GS > 7; N: Nonmalignant tissue. (a) Relative transcript levels: mRNA values are given after normalization to
TBP (TATA box binding protein) gene expression. (b) Serum protein levels: antigen concentrations are given in ng/mL.
components. The antigen levels of uPA and PAI-1 in serum
were not associated with prognosis of PCa patients neither in
univariate nor inmultivariate analysis (Table 2). Interestingly,
the OS was significantly different for the suPAR antigen
levels in Kaplan-Meier analysis (𝑃 = 0.022, log-rank test;
Figure 2). The OS of PCa patients with low/intermediate
preoperative suPAR serum levels averaged 144 months (95%
CI: 138–150 months). The patients with high uPAR serum
levels had a mean survival of 129 months (95% CI: 112–
142 months). Moreover, elevated suPAR concentrations in
serum were significantly associated with a distinctly higher
risk of death of PCa patients in both univariate (HR = 5.48,
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Figure 2: Association between uPAR protein concentration in
serum samples and OS. Eighty-one patients were separated accord-
ing to the 33% percentiles of serumuPAR protein concentration into
subgroups of low/intermediate (green: 0–66% percentile; 𝑛 = 54)
and high uPAR (red: >66–100% percentile; 𝑛 = 27) levels. OS was
significantly shorter in the patient group with high uPAR levels
compared with those patients with low/intermediate suPAR levels
(𝑃 = 0.022; log-rank test).
95%Cl: 1.06–28.29, 𝑃 = 0.042) and multivariate (HR = 7.12,
95%Cl: 1.25–40.69, 𝑃 = 0.027) Cox’s regression analyses
(adjusted to age, lymph node status, tumor stage, andGleason
score; Table 2). However, when the serum levels of uPA and
PAI-1 were additionally included into the multivariate Cox’s
regression analysis, suPAR lost its statistical significance for
OS (HR = 5.64, 95%Cl: 0.79–40.35; 𝑃 = 0.085; Table 2). This
may be caused by the significant positive correlation between
uPA and suPAR serum levels.
4. Discussion
The aim of this study was to investigate tissue mRNA
expression and serum antigen concentrations of uPA system
members and to assess potential associations with clinico-
pathological and prognostic parameters in PCa patients.
The number of PCa studies aimed at assessing mRNA
expression levels of uPA, uPAR, and PAI-1, particularly by
qPCR, is very limited (Supplemental Data Table 3). A previ-
ous report has shown significantly higher mRNA expression
levels of uPA and PAI-1, but not uPAR, in PCa tissue
compared to benign and normal prostate tissue [16]. In the
present study, no significant differences in mRNA expression
levels of uPAR or PAI-1 were found between malignant
and adjacent nonmalignant tissue of PCa patients. However,
the expression levels of uPA were significantly lower in
PCa tissue compared to the corresponding nonmalignant
tissue specimens. One explanation for these discrepancies
may be the different origin of nonmalignant tissue samples
used in the two studies. In contrast to our study, where
adjacent nonmalignant tissue was investigated, Riddick et
al. compared mRNA expression of uPA system components
in malignant tissues (44 PCa) with either benign prostatic
tissue (23 BPH patients) or normal prostatic tissues from
patients treated for bladder cancer [16]. In general, the cellular
composition and expression of uPA components in adjacent
nonmalignant tissue of PCa patients, as used in our study,
may be different from that of benign prostate tissue of BPH
patients. Furthermore, methodological differences in qPCR
techniques (different primers and reference genes) or the
composition of patient cohorts (different GS subgroups) may
further explain discrepancies in marker detection.
The cellular distribution of uPA system components has
been investigatedmainly in PCa tissue in comparison to BPH
specimens [25, 26]. uPA, uPAR, and PAI-1 were detected
in the majority of PCa and BPH tissues by both in situ
RNA hybridization and IHC. Marker expression was mainly
observed in different types of stromal and immune cells such
as fibroblasts, macrophages, or neutrophils, but not in cancer
cells or other epithelial cells [25]. Conversely, by analyzing
uPA and uPAR expression in PCa and BPH tissues using
the same techniques, Gavrilov et al. found expression signals
predominantly in adenocarcinoma cells of high grade PCa.
The stromal cells within tumor tissue and in BPH tissues
were mostly negative for both markers [26]. This controversy
regarding the staining patterns of uPA system components
in PCa or BPH tissues may be related to methodological
differences concerningmRNAhybridization or the specificity
of antibodies used for IHC [25]. No comparative study using
paired malignant and adjacent nonmalignant tissues from
PCa patients has been performed so far.
Significant correlations between the mRNA expression
levels of uPA, uPAR, and PAI-1 were detected in our study.
In agreement with these results, strong positive correlations
betweenmRNA values of uPA system components have been
observed in other types of cancer such as breast cancer, pan-
creatic adenocarcinoma, and soft tissue sarcomas [23, 24, 27–
30] but were not reported in PCa yet. Besides the established
fact of various protein/protein interactions of themembers of
the uPA system, the genes encoding them are likely regulated
in a concerted manner in tumor growth and metastasis,
for example, by the hypoxia-dependent transcription factor
HIF1𝛼 as shown for uPAR und PAI-1 [31] and by CD44 as
reported for uPA and uPAR [32].
A significant association between elevated mRNA levels
of uPA (Table 1(a)) and a higher GS was detected in our
study. However, our data showed no significant association
between mRNA levels of uPA system components and other
clinicopathological parameters such as tumor stage and
lymph node status of PCa patients.
So far, protein levels of uPA, uPAR, and/or PAI-1 in
tumor tissue from PCa patients were assessed by IHC studies
([13–15]; Supplemental Data Table 3). However, controversial
results were obtained regarding the association of uPA system
components with prognostically relevant clinicopathological
parameters [13–15]. Whereas in some studies [13, 14] high
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tissue levels of uPA, uPAR, and/or PAI-1 protein have been
shown to be significantly associated with clinical prognostic
parameters (GS, tumor stage, lymph node status, and tumor
resection status), others did not find significant associations
between high immunoexpression of uPA system components
and clinicopathological parameters [15]. The discrepancies
between these studies on protein immunostaining of the uPA
system components, as well the partial incoherency to our
mRNA-based study, indicate that there might be no clear
relation to GS, tumor stage, and lymph node status in PCa
patients.
In addition, we were interested whether the tissue mRNA
expression of the uPA system members was associated with
OS of PCa patients. However, no association between tissue
mRNA expression levels of the uPA system members and
OS of PCa patients was detected. Our results are consistent
with other studies that found no relationship between uPA,
uPAR, and/or PAI-1 mRNA expression and patients’ survival
in breast cancer, pancreatic cancer, and soft tissue sarcoma
[24, 29, 33]. Conversely, other studies have demonstrated that
mRNA expression levels of uPA system components were
linked to the prognosis of patients with various types of
cancer such as breast, pancreatic, gastric, or colorectal cancer
[27, 28, 30, 34–40].
In studies aimed at the analysis of the antigen concen-
trations of the uPA system members in blood, significant
associations of high uPA and/or suPAR levels with nonorgan-
confined, advanced disease [17, 20] or with a high GS [18]
of PCa patients, were observed (Supplemental Data Table
3). In the present study, we found no significant associa-
tions between serum levels of uPA system components and
clinicopathological parameters of PCa patients. Nevertheless,
elevated suPAR serum levels were significantly associated
with a shorter OS of PCa patients (log-rank test: 𝑃 = 0.022).
Furthermore, in multivariate Cox’s regression analyses, high
suPAR levels in serum were significantly associated with a
7-fold higher risk of death (of any cause) of PCa patients.
However, when the serum levels of all three uPA system
members were included simultaneously in the multivariate
Cox’s regression analysis for OS, suPAR level did not remain
a significant prognostic marker. This may be due to the
significant correlation between serum levels of uPA and
suPAR in the present PCa cohort. Our results are consistent
with previous reports that found a significant association
between high levels of suPAR in blood and poor prognosis of
PCa patients [17, 18, 20]. However, the design of these studies
differed from that of the present study.Miyake et al. measured
suPAR (and uPA) in serum from a cohort of PCa patients
composed of a high proportion of patients with distant
metastasis [17]. Significantly shorter OS of PCa patients with
elevated levels of suPAR and/or uPA, but not of the single
markers, was observed compared to patients with low levels
of both. In our study, we did not find an additive effect
on prognosis, when assessing combinations of uPA system
members (data not shown). Recently, Almasi et al. demon-
strated that elevated pretreatment levels of full-length suPAR
and cleaved forms of suPAR in serum were significantly
associated with shorter OS in a cohort of 131 patients with
metastatic PCa [20]. Unlike the studies mentioned above, the
PCa patient cohort in our retrospective study consisted of
nonselected patients with primary, clinically localized PCa
with a very low rate of distant metastasis.
In a study on uPAR and uPA levels in plasma of PCa
patients with clinically localized PCa, Shariat et al. reported
that high preoperative suPAR (and uPA) values were asso-
ciated with patients’ prognosis. However, in contrast to our
study, early biochemical progression as estimated by increase
in PSA values was used as end point for the prognostic
evaluation [18]. In our study, we present strong evidence
for the association of high suPAR serum levels with shorter
OS in a well-defined patient cohort with clinically localized
prostate cancer. Therefore, soluble uPAR measured in serum
or plasma of PCa patients is suggested to be a potential
prognostic marker for PCa patients. Similarly, high serum
levels of suPAR were reported to be associated with worse
prognosis in several studies on other types of cancer [for
review see [41, 42]].
All in all, the present status of results concerning asso-
ciations of uPA system members at the mRNA and protein
level in tumor tissue with clinicopathological parameters
in PCa strongly implies a standardized, prospective study
of the uPA system in PCa tissues. The association of high
suPAR levels with poor survival of patients with PCa or other
cancers indicates a prognostic impact of suPAR antigen levels
measured in blood.
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